Dna-binding Protein-A Modulator for the Treatment of Renal Ischemia/reperfusion Injury

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses the use of compounds that modulate or inhibit the activity of DNA-binding protein-A (DbpA), a cold shock protein, for the treatment of acute kidney injury (AKI), particularly resulting from ischemia/reperfusion injury. The inventors found that DbpA plays a crucial role in promoting kidney tubular cell damage after such injury, and that blocking or reducing DbpA through specific molecules—such as miRNA-191, various antisense RNAs, or antibodies—can protect kidney function, reduce inflammation, and prevent fibrosis. The approach can be used alone or in combination with other drugs commonly used for AKI.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of patients experiencing acute kidney injury due to ischemia/reperfusion events, such as those occurring during kidney transplantation, cardiac surgery, or traumatic blood loss.
• Prophylactic administration in patients at high risk of AKI (e.g., prior to major surgeries where kidney perfusion may be interrupted).
• Combination therapies for AKI involving DbpA modulators with standard AKI medications (e.g., radical scavengers, receptor antagonists) to enhance treatment efficacy.
• Research applications to study the role of DbpA in kidney injury and potential drug development for other organ ischemia/reperfusion injuries.

BenefitsContent extracted from patent full text and abstract with AI.

• Novel therapeutic pathway targeting a previously unexploited molecular driver (DbpA) of kidney injury, potentially improving patient outcomes.
• Ability to use a variety of molecules (miRNAs, siRNAs, shRNAs, antisense oligonucleotides, antibodies) increases flexibility in drug development and optimization.
• Proven protection in animal models, showing improved kidney function, reduced cellular damage, and minimized inflammation and fibrosis.
• Potential to combine with current therapies, possibly providing synergistic benefits and addressing multiple disease mechanisms in AKI.
• May also reduce the occurrence of chronic kidney disease and subsequent complications after an initial acute injury.
• Offers prophylactic and therapeutic applications, extending utility to prevention in high-risk settings.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a DNA-binding protein-A (DbpA) modulating compound for use in the treatment of an acute kidney injury (AKI). In addition, the present invention relates to a combination of a DbpA modulating compound and a drug different from a DbpA modulating compound for use in the treatment of an acute kidney injury (AKI).